BRD2 and gastric cancer: Despite recent findings that CAF-derived HAPLN1 promotes tumor invasion in gastric cancer (24), our data reveal that HAPLN1 is predominantly expressed in NAT tissues, with expression levels sharply decreasing in tumor tissues.